Over expression of CDC20 may be a potential biomarker for prediction of biochemical recurrence after radical prostatectomy of clinically localized PCa.[29] The present study revealed that CDC20 and PTTG1 contribute more to migration, progression, and poorer prognoses in metastatic prostate cancer (mPCa) compared with PCa. This evidence concerns the gene CDC20 and metastatic prostate carcinoma.